Blog
RSS FeedPosted by Michael Wonder on 14 Oct 2020
Evidence for HTA: innovative methods for challenging times
13 October 2020 - Dalia Dawoud, Scientific Adviser at NICE Science, Evidence and Analytics Directorate explains NICE’s role as co-host of ...
Posted by Michael Wonder on 12 Oct 2020
NICE proposes simplifying how medicines and medical devices are selected for evaluation
12 October 2020 - As part of the work underway to review the methods and processes NICE uses to develop guidance ...
Posted by Michael Wonder on 07 Oct 2020
NICE terminates yet another appraisal
7 October 2020 - 9 of the last 20 published technology appraisals have been terminated. ...
Posted by Michael Wonder on 01 Oct 2020
NICE backs Shionogi's Rizmoic
1 October 2020 - Shionogi's Rizmoic (naldemedine) will be available on the National Health Service to treat patients with opioid-induced ...
Posted by Michael Wonder on 29 Sep 2020
The estimation of health state utility values in rare diseases: overview of existing techniques
25 September 2020 - There are several techniques for estimating health state utility values, each of which presents pros and cons ...
Posted by Michael Wonder on 23 Sep 2020
NICE board agrees to stimulate action following publication of Independent Medicines and Medical Devices Safety Review report
23 September 2020 - NICE to reinforce the importance of collaborative working with system partners to ensure a more integrated approach ...
Posted by Michael Wonder on 23 Sep 2020
NICE publishes final guidance for another Roche cancer medicine
23 September 2020 - This time it is for polatuzumab vedotin (Polivy) for patients with non-Hodgkin's lymphoma. ...
Posted by Michael Wonder on 22 Sep 2020
NICE publishes draft guidance on new use for Kyprolis
22 September 2020 - The guidance relates to the use of carfilzomib with dexamethasone and lenalidomide for patients with previously ...
Posted by Michael Wonder on 18 Sep 2020
BMS' Opdivo wins new NICE lung cancer backing
18 September 2020 - NICE has published draft guidance recommending Bristol-Myers Squibb's Opdivo (nivolumab) as a second-line treatment option for ...
Posted by Michael Wonder on 18 Sep 2020
NICE U-turn sees Akcea's Waylivra win NHS funding
18 September 2020 - Akcea Therapeutics UK's Waylivra (volanesorsen), the first and only therapy for Familial Chylomicronaemia Syndrome (FCS), will ...
Posted by Michael Wonder on 17 Sep 2020
NICE announces autumn series of virtual events
17 September 2020 - Three webinar style events will feature a number of high-profile speakers. ...
Posted by Michael Wonder on 15 Sep 2020
NICE joins global alliance to shine spotlight on evidence-based health care
15 September 2020 - Tuesday 20 October will be the inaugural world evidence-based health care day. ...
Posted by Michael Wonder on 12 Sep 2020
NICE widens its Zolgensma appraisal due to European Marketing Authorisation
11 September 2020 - England’s NICE is expanding its appraisal of Zolgensma, a gene therapy for spinal muscular atrophy, according ...
Posted by Michael Wonder on 11 Sep 2020
NICE chief executive and chairman thank non-executive director for his service as he announces resignation
11 September 2020 - Professor Martin Cowie stands down from the NICE board following his appointment to a role at Astra ...
Posted by Michael Wonder on 11 Sep 2020
Improved agreement means NICE now recommends lung cancer treatment
11 September 2020 - Thousands of people with non-small-cell lung cancer (NSCLC) will benefit from draft guidance published today by NICE. ...